3.76
-0.24 (-6%)
3.78
+0.02 (+0.53%)
CHMA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. CHMA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CHMA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year CHMA has reported negative net income.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.38% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -2408.65% | ||
| PM (TTM) | -2968.35% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- CHMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- CHMA has an Altman-Z score of -3.09. This is a bad value and indicates that CHMA is not financially healthy and even has some risk of bankruptcy.
- There is no outstanding debt for CHMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.09 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 7.91 indicates that CHMA has no problem at all paying its short term obligations.
- A Quick Ratio of 7.08 indicates that CHMA has no problem at all paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.91 | ||
| Quick Ratio | 7.08 |
3. Growth
3.1 Past
- CHMA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -46.36%.
EPS 1Y (TTM)-46.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, CHMA will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.36% on average per year.
- CHMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 280.08% yearly.
EPS Next Y12.13%
EPS Next 2Y22.91%
EPS Next 3Y28.31%
EPS Next 5Y15.36%
Revenue Next Year1731.35%
Revenue Next 2Y702.55%
Revenue Next 3Y405.04%
Revenue Next 5Y280.08%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- CHMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CHMA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -1.42 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as CHMA's earnings are expected to grow with 28.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.91%
EPS Next 3Y28.31%
5. Dividend
5.1 Amount
- No dividends for CHMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Chiasma Inc / CHMA FAQ
What is the ChartMill fundamental rating of Chiasma Inc (CHMA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to CHMA.
Can you provide the valuation status for Chiasma Inc?
ChartMill assigns a valuation rating of 1 / 10 to Chiasma Inc (CHMA). This can be considered as Overvalued.
Can you provide the profitability details for Chiasma Inc?
Chiasma Inc (CHMA) has a profitability rating of 1 / 10.
What is the expected EPS growth for Chiasma Inc (CHMA) stock?
The Earnings per Share (EPS) of Chiasma Inc (CHMA) is expected to grow by 12.13% in the next year.